Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.53 |
| ▸ | BCKDK | O14874 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10481468 | 0.88 | LMNA (0.48) | RXFP1MCL1BCKDKNPC1RAB9A | |
| SCHEMBL3200456 | 0.86 | RXFP1 (0.44) | RXFP1MCL1BCKDKNPC1RAB9A | |
| SCHEMBL15619136 | 0.85 | MCL1 (0.53) | RXFP1MCL1BCKDKNPC1RAB9A | |
| SCHEMBL25212927 | 0.84 | RXFP1 (0.51) | RXFP1MCL1BCKDKNPC1RAB9A | |
| SCHEMBL8142110 | 0.84 | KDM4E (0.64) | RXFP1MCL1BCKDKNPC1RAB9A | |
| SCHEMBL31015960 | 0.84 | RXFP1 (0.51) | RXFP1MCL1BCKDKNPC1RAB9A | |
| SCHEMBL25257143 | 0.84 | RXFP1 (0.51) | RXFP1MCL1BCKDKNPC1RAB9A | |
| SCHEMBL31015931 | 0.84 | KDM4E (0.64) | RXFP1MCL1BCKDKNPC1RAB9A | |
| SCHEMBL31015986 | 0.84 | RXFP1 (0.51) | RXFP1MCL1BCKDKNPC1RAB9A | |
| SCHEMBL13926048 | 0.83 | BCL2L1 (0.51) | MCL1NPC1RAB9AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048901-B2 | 5-{3-[3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-propyl}-2H-tetrazole; metabolic disorders, insulin resistance, dyslipidemia, Syndrome X | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20090048286-A1 | Inhibitors of Protein Tyrosine Phosphatase 1B | WYETH (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048286-A1 | Inhibitors of Protein Tyrosine Phosphatase 1B | WYETH (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048286-A1 | Inhibitors of Protein Tyrosine Phosphatase 1B | WYETH (US) | 2009-02-19 | — | — | US | disclosed |
| US-20080249126-A1 | 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES HAVING ACIDIC, MOSTLY HETEROCYCLIC GROUPS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20050203081-A1 | Inhibitors of protein tyrosine phosphatase 1B | WYETH | 2005-09-15 | — | — | US | disclosed |
| WO-2005081960-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B | WYETH (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20040209932-A1 | 1,3-substitued cycloalkyl derivatives having acidic, mostly heterocyclic groups; processes for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249126-A1 | 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES HAVING ACIDIC, MOSTLY HETEROCYCLIC GROUPS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | GPR119, PC, FFAR1 | RXFP1 2358/4885MCL1 2050/4885BCKDK 57/4885 |
| US-20050203081-A1 | Inhibitors of protein tyrosine phosphatase 1B | PTPRS, PTPRO, PTPRM | RXFP1 3889/4885MCL1 1825/4885BCKDK 2152/4885 |
| US-20040209932-A1 | 1,3-substitued cycloalkyl derivatives having acidic, mostly heterocyclic groups; processes for their preparation and their use as pharmaceuticals | GPR119, PC, CPT1A | RXFP1 2318/4885MCL1 1964/4885BCKDK 47/4885 |
| US-20090048286-A1 | Inhibitors of Protein Tyrosine Phosphatase 1B | PTPRS, PTPRO, PTPRM | RXFP1 3889/4885MCL1 1825/4885BCKDK 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.